Morgan Stanley resumed coverage on Rubius Therapeutics with a new price target

10/19/21 8:48:42 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Morgan Stanley resumed coverage of Rubius Therapeutics with a rating of Equal-Weight and set a new price target of $22.00 from $25.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RUBY

Date	Price Target	Rating	Analyst
9/13/2022		Buy → Neutral	Guggenheim
2/25/2022	$14.00 → $5.00	Market Perform	SVB Leerink
11/9/2021	$20.00 → $14.00	Market Perform	SVB Leerink
10/19/2021	$25.00 → $22.00	Equal-Weight	Morgan Stanley